• Revium Rx posted a net loss of USD 725,000 for the quarter ended March 31, 2026, widening 14.3% year over year.
• Operating loss edged up 0.2% to USD 739,000 as research and development expense more than doubled to USD 473,000.
• General and administrative expense fell 48.7% to USD 266,000, while financing income slid to USD 14,000 on lower interest income from bank deposits.
• Program update: Israeli Ministry of Health approval on Feb. 18, 2026 cleared Nano-Mupirocin Phase 1 trials in healthy volunteers; cash and cash equivalents and short-term bank deposits totaled about USD 2.1 million as of March 31, 2026, with substantial doubt flagged about going-concern ability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revium Rx. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-056600), on May 14, 2026, and is solely responsible for the information contained therein.